- ISIN
- US74065P1012
- CUSIP
- 74065P101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 25, 2020
Highlights
- Market Cap
- $261.89M
- Enterprise Value
- $260.62M
- EPS (TTM)
- -$1.05
- Total Revenue (TTM)
- $16.72M
- Gross Profit (TTM)
- $11.30M
- EBITDA (TTM)
- -$82.17M
- Year Range
- $0.75 - $5.69
- Target Price
- $8.00
- ROA (TTM)
- -65.03%
- ROE (TTM)
- -129.27%
- Avg. Volume (1M)
- 369K
- Avg. Volume Value (1M)
- $1.68M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PRLD Performance Chart
Prelude Therapeutics Incorporated (PRLD) is up 58.6% since the beginning of the year. At $5 per share, PRLD is trading 19.2% below its 52-week high of $6. Investors who bought $1,000 worth of PRLD shares 5 years ago would now be looking at an investment worth $144.
Loading charts...
Compare this symbol against anything
Returns By Period
Prelude Therapeutics Incorporated (PRLD) has returned 58.62% so far this year and 455.35% over the past 12 months.
Prelude Therapeutics Incorporated
- 1D
- -8.91%
- 1M
- -6.31%
- 6M
- 148.65%
- YTD
- 58.62%
- 1Y
- 455.35%
- 3Y*
- 7.62%
- 5Y*
- -32.17%
- 10Y*
- —
- ALL TIME*
- -25.26%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
PRLD Monthly Returns History
Based on dividend-adjusted daily data since Sep 25, 2020, PRLD's average daily return is +0.15%, while the average monthly return is +1.59%. At this rate, an investment would double in approximately 3.7 years.
Historically, 42% of months were positive and 58% were negative. The best month was Nov 2023 with a return of +95.9%, while the worst month was Sep 2024 at -60.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, PRLD closed higher 47% of trading days. The best single day was Nov 3, 2025 with a return of +150.3%, while the worst single day was Nov 4, 2025 at -55.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -36.21% | 49.19% | 23.91% | 52.92% | -25.05% | 35.97% | -13.70% | 58.62% | |||||
| 2025 | -13.73% | -31.00% | 1.19% | 24.96% | -7.69% | -8.64% | -3.64% | 55.15% | 19.01% | 10.42% | 5.66% | 72.62% | 127.45% |
| 2024 | -23.19% | 31.10% | 10.23% | -20.46% | 2.12% | -1.04% | 67.19% | -18.37% | -60.19% | -42.03% | -12.50% | 21.43% | -70.14% |
| 2023 | 5.63% | -11.29% | 0.71% | 13.33% | -13.62% | -19.35% | -13.11% | -4.60% | -17.16% | -45.31% | 95.86% | 29.00% | -29.30% |
| 2022 | -20.24% | -11.08% | -21.86% | -33.48% | -8.50% | 24.29% | -4.21% | 44.00% | -8.19% | 1.21% | -0.30% | -9.45% | -51.49% |
| 2021 | -9.22% | -4.03% | -30.48% | -4.36% | -16.12% | -17.64% | 11.91% | 11.39% | -12.44% | -43.74% | -18.71% | -12.88% | -82.60% |
Benchmark Metrics
Prelude Therapeutics Incorporated has an annualized alpha of 13.58%, beta of 1.52, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 25, 2020.
- This stock participated in 106.56% of S&P 500 Index downside but only -29.13% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.58%
- Beta
- 1.52
- R²
- 0.04
- Upside Capture
- -29.13%
- Downside Capture
- 106.56%
Return for Risk
Risk / Return Rank
PRLD ranks 96 for risk / return — above 96% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Prelude Therapeutics Incorporated (PRLD) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PRLD | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.06 | ||
| Sortino ratioReturn per unit of downside risk | +1.75 | ||
| Omega ratioGain probability vs. loss probability | 1.53 | 1.25 | +0.28 |
| Calmar ratioReturn relative to maximum drawdown | 7.05 | 2.00 | +5.04 |
| Martin ratioReturn relative to average drawdown | 15.63 | 8.49 | +7.14 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Prelude Therapeutics Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Prelude Therapeutics Incorporated was 99.33%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Prelude Therapeutics Incorporated drawdown is 94.98%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.33%Apr 2025 | 4y 1mo | — | 5y 5moFeb 2021 - now | 2025 selloff2025 |
-36.23%Oct 2020 | 13d | 15d | 28dOct 2020 - Nov 2020 | — |
-32.75%Jan 2021 | 8d | 1mo 5d | 1mo 13dDec 2020 - Feb 2021 | — |
-17.47%Nov 2020 | 5d | 15d | 20dNov 2020 - Dec 2020 | — |
-14.10%Nov 2020 | 4d | 3d | 7dNov 2020 - Nov 2020 | — |
Drawdown Indicators
| PRLD | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.33% | -56.78% | -42.55% |
Max Drawdown (1Y)Largest decline over 1 year | -70.10% | -9.10% | -61.00% |
Max Drawdown (3Y)Largest decline over 3 years | -90.42% | -18.90% | -71.52% |
Max Drawdown (5Y)Largest decline over 5 years | -98.42% | -25.43% | -72.99% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -94.98% | -1.58% | -93.40% |
Average DrawdownAverage peak-to-trough decline | -85.39% | -10.70% | -74.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.55% | 2.14% | +29.41% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Prelude Therapeutics Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Prelude Therapeutics Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PRLD relative to other companies in the Biotechnology industry. Currently, PRLD has a P/S ratio of 20.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PRLD in comparison with other companies in the Biotechnology industry. Currently, PRLD has a P/B value of 6.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PRLD
Add Prelude Therapeutics Incorporated to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PRLD